Guillain‐Barré syndrome in a patient with antibodies against SARS‐COV‐2

To the editor,There are now several reports on neurologic features of SARS-CoV-2 infection [1,2].In a recent study of 214 patients with COVID-19, 78 (36.4%) patients had neurological manifestations, including headache, dizziness, acute cerebrovascular diseases, and impaired consciousness [2].Helms et al. report neurologic features in 84% (49/58) of patients with severe SARS-CoV-2 infection presenting with acute respiratory distress syndrome [1].In this case series, neurological signs and symptoms included encephalopathy, prominent agitation and confusion, and corticospinal tract signs.Other reports suggest para-and post-infectious neurologic diseases associated with SARS-CoV-2 infection, including Guillain-Barr e syndrome, Miller Fisher Syndrome and polyneuritis cranialis [3,4].Here, we report a case of Guillain-Barr e syndrome (GBS) with an onset 2 weeks after SARS-CoV-2 infection with highly elevated serum antibodies against SARS-CoV-2, which supports the association between SARS-CoV-2 disease and the GBS.